Natzold 5mg Injection

• Hypercalcemia
• Osteoporosis

Side effects are unwanted symptoms that can occur from any medical treatment. Like other medications, the Natzold 5mg Injection can also have adverse effects on the body, most of which resolve without the need for medical attention.

Some common side effects include:

• Headache
  
• Back pain
  
• Musculoskeletal (bone, muscle or joint) pain
  
• Heartburn
  
• Diarrhea
  
• Fever
  
• Anemia (low number of red blood cells)
  
• Fatigue
  
• Bone pain
  
• Nausea
  
• Vomiting

Seek medical attention in case of any unusual or severe side effects immediately.

• A medical professional or nurse administers the Natzold Infusion.
• The doctor will determine how much and how often it will be given.
• Depending on your underlying medical condition, a patient could only require one injection or several.
• In order to prevent dehydration, doctor will advise to drink a lot of water before the injection.
• It can take a few days to get maximum benefit from this medication.

• Natzold 5mg Injection is a prescription based medicine with active ingredient Zoledronic Acid which is a bisphosphonate.
• It works by suppressing the activity of osteoclasts, cells that cause destruction of bone.
• This strengthens the bones as well as minimizes the risk of fractures.
  

• Perry, C. M., & Figgitt, D. P. (2004). Zoledronic acid: a review of its use in patients with advanced cancer. Drugs, 64(11), 1197-1211.
  
• Wellington, K., & Goa, K. L. (2003). Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy. Drugs, 63(4), 417-437.
  
• Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., ... & Boonen, S. (2007). Zoledronic acid and clinical fractures and mortality after hip fracture. New England Journal of Medicine, 357(18), 1799-1809.
  
• Coleman, R. E., Marshall, H., Cameron, D., Dodwell, D., Burkinshaw, R., Keane, M., ... & Bell, R. (2011). Breast-cancer adjuvant therapy with zoledronic acid. New England Journal of Medicine, 365(15), 1396-1405.
  
• Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., ... & Cummings, S. R. (2007). Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. New England Journal of Medicine, 356(18), 1809-1822.